TD Asset Management Inc Purchases 19,340 Shares of Ralliant Corporation $RAL

TD Asset Management Inc grew its position in shares of Ralliant Corporation (NYSE:RAL) by 9.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 232,520 shares of the company’s stock after buying an additional 19,340 shares during the period. TD Asset Management Inc owned approximately 0.21% of Ralliant worth $11,838,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Danske Bank A S bought a new position in Ralliant during the 4th quarter worth $25,000. Allworth Financial LP grew its holdings in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Ralliant during the 4th quarter worth $26,000. Palisade Asset Management LLC acquired a new stake in shares of Ralliant during the 3rd quarter worth $26,000. Finally, Rothschild Investment LLC grew its holdings in shares of Ralliant by 98.1% during the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after purchasing an additional 303 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RAL. Barclays increased their target price on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Citigroup increased their target price on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Royal Bank Of Canada increased their target price on Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 13th. Wall Street Zen lowered Ralliant from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Finally, TD Cowen increased their target price on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $64.50.

Ralliant Stock Performance

NYSE:RAL opened at $61.16 on Tuesday. The stock’s 50-day simple moving average is $51.16 and its 200 day simple moving average is $49.32. The firm has a market capitalization of $6.85 billion and a PE ratio of -5.59. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $63.31.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, analysts anticipate that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.